The global economy’s fluctuations in 2026, characterized by shifting trade policies and "Most Favored Nation" (MFN) drug pricing reforms in the US, have created a complex environment for biopharma. The Restless Legs Syndrome Market Economic Outlook remains cautiously optimistic, as the "essential" nature of sleep health protects the market from the worst of discretionary spending...